Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001437749-14-011096
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-12 17:09:25
Reporting Period:
2014-06-10
Filing Date:
2014-06-12
Accepted Time:
2014-06-12 17:09:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1484478 Furiex Pharmaceuticals Inc. FURX Pharmaceutical Preparations (2834) 271197863
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1590795 Sailash Patel C/o Furiex Pharmaceuticals, Inc.,
3900 Paramount Parkway, Suite 150
Morrisville NC 27560
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-06-10 1,504 $104.68 26,444 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (to buy) $9.11 2020-06-17 59,288 59,288 Direct
Common Stock Stock Options (to buy) $15.00 2021-05-09 20,000 20,000 Direct
Common Stock Stock Options (to buy) $13.16 2021-10-03 29,644 29,644 Direct
Common Stock Stock Options (to buy) $17.80 2022-02-24 8,294 8,294 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2020-06-17 59,288 59,288 Direct
2021-05-09 20,000 20,000 Direct
2021-10-03 29,644 29,644 Direct
2022-02-24 8,294 8,294 Direct
Footnotes
  1. Represents shares sold in connection with the satisfaction of tax liabilities incurred upon the vesting of restricted stock granted June 10, 2013.
  2. All options became 100% vested on June 11, 2014 in connection with the Agreement and Plan of Merger dated as of April 27, 2014 by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc.